WINTON GROUP Ltd Invests $1.34 Million in Summit Therapeutics PLC $SMMT

WINTON GROUP Ltd purchased a new stake in shares of Summit Therapeutics PLC (NASDAQ:SMMT) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 64,900 shares of the company’s stock, valued at approximately $1,341,000.

Several other institutional investors have also recently made changes to their positions in SMMT. Vanguard Group Inc. increased its holdings in Summit Therapeutics by 31.2% during the third quarter. Vanguard Group Inc. now owns 11,379,728 shares of the company’s stock valued at $235,105,000 after buying an additional 2,706,056 shares during the last quarter. Norges Bank purchased a new position in shares of Summit Therapeutics during the 2nd quarter worth $29,576,000. APEIRON CAPITAL Ltd grew its position in shares of Summit Therapeutics by 9.2% during the 3rd quarter. APEIRON CAPITAL Ltd now owns 1,310,941 shares of the company’s stock valued at $27,084,000 after acquiring an additional 110,000 shares during the period. Fiera Capital Corp purchased a new stake in shares of Summit Therapeutics in the 2nd quarter worth $16,659,000. Finally, Bank of America Corp DE increased its stake in shares of Summit Therapeutics by 53.3% in the 2nd quarter. Bank of America Corp DE now owns 566,147 shares of the company’s stock worth $12,048,000 after purchasing an additional 196,925 shares in the last quarter. Institutional investors own 4.61% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on SMMT shares. Piper Sandler set a $40.00 price objective on Summit Therapeutics in a research report on Wednesday, January 14th. HC Wainwright lowered their price target on shares of Summit Therapeutics from $40.00 to $30.00 and set a “buy” rating on the stock in a report on Tuesday, February 24th. Summit Redstone set a $18.00 price target on shares of Summit Therapeutics in a research report on Wednesday, December 17th. Barclays raised shares of Summit Therapeutics from an “underweight” rating to an “equal weight” rating and increased their price objective for the stock from $16.00 to $18.00 in a research note on Wednesday, December 17th. Finally, Citigroup restated a “buy” rating on shares of Summit Therapeutics in a research note on Tuesday, February 24th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, four have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $32.25.

Summit Therapeutics Stock Down 1.6%

SMMT stock opened at $16.07 on Thursday. Summit Therapeutics PLC has a 52 week low of $13.83 and a 52 week high of $36.91. The firm has a market capitalization of $12.46 billion, a P/E ratio of -11.08 and a beta of -1.43. The company has a fifty day simple moving average of $16.13 and a two-hundred day simple moving average of $18.34.

Summit Therapeutics (NASDAQ:SMMT) last issued its quarterly earnings data on Monday, February 23rd. The company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.07). As a group, analysts anticipate that Summit Therapeutics PLC will post -0.3 EPS for the current year.

Summit Therapeutics Company Profile

Summit Therapeutics plc is a clinical‐stage biotechnology company dedicated to the discovery and development of precision medicines for serious and life‐threatening diseases. The company applies a targeted approach to drug design, focusing on novel mechanisms of action that differentiate its candidates from existing therapies.

Summit’s lead asset, ridinilazole (formerly SMT19969), is being developed to treat Clostridioides difficile infections and has received both Fast Track and Qualified Infectious Disease Product designations from the U.S.